A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
Allogene Therapeutics and SpringWorks Therapeutics have launched a clinical trial collaboration to conduct a Phase…
Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple…
Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion…
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe…
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “…
Older multiple myeloma patients who are unable to receive a stem cell transplant could receive Ninlaro (ixazomib) as part of their first line-therapy instead…
A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to…
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free…